ozdogan_md· @ozdogan_md · X·· 2 天前评分60
正文 · 原文
After osimertinib, can we target resistance rather than move straight to chemo? SAFFRON: osimertinib + savolitinib vs platinum–pemetrexed in EGFRm/MET-OE/AMP NSCLC. PFS/OS toplines are positive; magnitude + safety await LBA6. Prof. Shun Lu @myESMO @IASLC #ESMO26 #LCSM https://t.co/Zyt7CbatSz
热度 9 · 5 赞 · 0 回复 · 4 转发
来源：ozdogan_md · x.com